BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:tulisokibart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of tulisokibart\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07486960-2@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07486960)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: Study to Evaluate Tulisokibart 
 in Adults With Psoriatic Arthritis (MK-7240-015)\nEstimated primary comple
 tion: 17 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07486960
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133633-2@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07133633)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: A Clinical Study of Tulisokibar
 t (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)\nE
 stimated primary completion: 29 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/tulisokibart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07133633
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06430801-2@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:tulisokibart: Phase 3 readout est. (NCT06430801)
DESCRIPTION:tulisokibart\, phase 3\, Crohn's Disease.\nStudy: A Study to Ev
 aluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants W
 ith Moderate to Severe Crohn's Disease (MK-7240-008)\nEstimated primary co
 mpletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06430801
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07861074-2@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20290605
DTEND;VALUE=DATE:20290606
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07861074)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: A Clinical Trial Of Tulisokibar
 t In Participants With Active\, Non-Infectious Uveitis (MK-7240-019)\nEsti
 mated primary completion: 5 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tulisokibart#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07861074
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867938-2@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20291005
DTEND;VALUE=DATE:20291006
SUMMARY:tulisokibart: Phase 2 readout est. (NCT07867938)
DESCRIPTION:tulisokibart\, phase 2.\nStudy: A Clinical Trial of Tulisokibar
 t (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)\nEsti
 mated primary completion: 5 October 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tulisokibart#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07867938
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651281-2@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20371217
DTEND;VALUE=DATE:20371218
SUMMARY:tulisokibart: Phase 3 readout est. (NCT06651281)
DESCRIPTION:tulisokibart\, phase 3\, Ulcerative Colitis.\nStudy: Extension 
 Study of Long-term Safety and Efficacy of Tulisokibart in Participants Wit
 h Crohn's Disease or Ulcerative Colitis (MK-7240-011)\nEstimated primary c
 ompletion: 17 December 2037. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tulisokibart#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06651281
URL:https://assetmemo.bio/drug/tulisokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
